Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
Patent Issuance: Nutriband Inc. has received a new patent for its AVERSA™ transdermal abuse deterrent technology, expanding its intellectual property protection in the U.S. and internationally across 46 countries.
Product Development: The company is developing an abuse-deterrent fentanyl patch, which could potentially generate annual U.S. sales between $80 million to $200 million, aimed at preventing drug misuse and ensuring safety for patients.
Trade with 70% Backtested Accuracy
Analyst Views on NTRBW
No data
About the author
NUTRIBAND INC - NAME CHOSEN FOR REGISTRATION WITH US PATENT AND TRADEMARK OFFICE
- Patent and Trademark Office Submission: A list of selected names has been submitted to the U.S. Patent and Trademark Office for registration.
- Nutriband Inc.: The submission is related to the company Nutriband Inc., indicating potential new branding or product developments.
NUTRIBAND INC CHOOSES BRAND NAME FOR ABUSE-RESISTANT FENTANYL PATCH; PLANS FDA SUBMISSION
Commercial Brand Name Selection: Nutriband has chosen a commercial brand name for its fentanyl patch, which is intended for abuse deterrence.
Submission to FDA: The company plans to submit this new product to the FDA for approval, aiming to enhance safety and reduce misuse.
Nutriband Partners with Brand Institute to Create a Commercial Name for Its Abuse-Resistant Fentanyl Patch
Nutriband's Product Development: Nutriband has partnered with Brand Institute to develop a worldwide brand name and visual identity for its lead product, an abuse-deterrent fentanyl transdermal system known as AVERSA™ FENTANYL.
Technology and Safety Features: The AVERSA™ technology aims to prevent the abuse and accidental exposure of opioids, with a strong intellectual property portfolio protecting its innovations across multiple countries.
Nutriband Inc. Reports Record Q2 2025 Revenue Growth of 50.87% Year-Over-Year and Advances in NDA Filing for AVERSA Fentanyl
Financial Performance: Nutriband Inc. reported a revenue increase of 50.87% year-over-year, totaling $1,289,884 for the six months ending July 31, 2025, and holds cash reserves of $6.9 million to support product development.
Product Development: The company is advancing its lead product, AVERSA™ Fentanyl, which may become the first abuse-deterrent transdermal patch globally, with potential peak annual sales estimated between $80-$200 million.
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
CEO Transition: Gareth Sheridan, CEO of Nutriband Inc., will temporarily step down to run for the Irish Presidential election, with Chairman Serguei Melnik taking over as interim CEO during this period.
AVERSA Fentanyl Development: Nutriband's AVERSA Fentanyl patch, designed to deter abuse and misuse, has received FDA approval for a meeting request, with potential annual US sales estimated between $80 million to $200 million.
FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
FDA Meeting for AVERSA™ FENTANYL: The FDA has scheduled a Type C Meeting on September 18, 2025, to provide feedback on the Chemistry, Manufacturing, and Controls plans for Nutriband's AVERSA™ FENTANYL, an abuse-deterrent transdermal fentanyl patch developed in partnership with Kindeva.
Potential Impact of AVERSA™ Technology: Nutriband's AVERSA™ technology aims to enhance the safety profile of transdermal drugs by preventing abuse and accidental exposure, with projected annual US sales reaching between $80 million to $200 million while addressing global pain management needs.
NUTRIBAND INC - NAME CHOSEN FOR REGISTRATION WITH US PATENT AND TRADEMARK OFFICE
- Patent and Trademark Office Submission: A list of selected names has been submitted to the U.S. Patent and Trademark Office for registration.
- Nutriband Inc.: The submission is related to the company Nutriband Inc., indicating potential new branding or product developments.
NUTRIBAND INC CHOOSES BRAND NAME FOR ABUSE-RESISTANT FENTANYL PATCH; PLANS FDA SUBMISSION
Commercial Brand Name Selection: Nutriband has chosen a commercial brand name for its fentanyl patch, which is intended for abuse deterrence.
Submission to FDA: The company plans to submit this new product to the FDA for approval, aiming to enhance safety and reduce misuse.
Nutriband Partners with Brand Institute to Create a Commercial Name for Its Abuse-Resistant Fentanyl Patch
Nutriband's Product Development: Nutriband has partnered with Brand Institute to develop a worldwide brand name and visual identity for its lead product, an abuse-deterrent fentanyl transdermal system known as AVERSA™ FENTANYL.
Technology and Safety Features: The AVERSA™ technology aims to prevent the abuse and accidental exposure of opioids, with a strong intellectual property portfolio protecting its innovations across multiple countries.
Nutriband Inc. Reports Record Q2 2025 Revenue Growth of 50.87% Year-Over-Year and Advances in NDA Filing for AVERSA Fentanyl
Financial Performance: Nutriband Inc. reported a revenue increase of 50.87% year-over-year, totaling $1,289,884 for the six months ending July 31, 2025, and holds cash reserves of $6.9 million to support product development.
Product Development: The company is advancing its lead product, AVERSA™ Fentanyl, which may become the first abuse-deterrent transdermal patch globally, with potential peak annual sales estimated between $80-$200 million.
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
CEO Transition: Gareth Sheridan, CEO of Nutriband Inc., will temporarily step down to run for the Irish Presidential election, with Chairman Serguei Melnik taking over as interim CEO during this period.
AVERSA Fentanyl Development: Nutriband's AVERSA Fentanyl patch, designed to deter abuse and misuse, has received FDA approval for a meeting request, with potential annual US sales estimated between $80 million to $200 million.
FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
FDA Meeting for AVERSA™ FENTANYL: The FDA has scheduled a Type C Meeting on September 18, 2025, to provide feedback on the Chemistry, Manufacturing, and Controls plans for Nutriband's AVERSA™ FENTANYL, an abuse-deterrent transdermal fentanyl patch developed in partnership with Kindeva.
Potential Impact of AVERSA™ Technology: Nutriband's AVERSA™ technology aims to enhance the safety profile of transdermal drugs by preventing abuse and accidental exposure, with projected annual US sales reaching between $80 million to $200 million while addressing global pain management needs.
